Literature DB >> 16099079

Costs of running a universal adolescent hepatitis B vaccination programme.

L A Wallace1, D Young, A Brown, J C Cameron, S Ahmed, R Duff, W F Carman, N R E Kitchin, J S Nguyen-Van-Tam, D J Goldberg.   

Abstract

In the first UK study to examine feasibility and acceptability of universal adolescent hepatitis B vaccination, the costs associated with the administration and uptake (80.2 and 89.3% for three doses and at least two doses, respectively), of a three-dose regimen in pupils in Glasgow schools (2001/2002) were measured. These data were used to estimate the economic outlay for the delivery of a routine, ongoing three-dose and two-dose hepatitis B vaccine programme in schools. Vaccine, accounting for almost 70% of the overall costs, was the largest cost item for both the pilot and routine programmes, using either regimen. However, the ongoing, two-dose regimen was the cheapest option in this analysis, irrespective of vaccine price. Cost data from this study may be useful for other countries wishing to implement a similar programme.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16099079     DOI: 10.1016/j.vaccine.2005.06.034

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

Review 1.  Should universal hepatitis B immunisation be introduced in the UK?

Authors:  P English
Journal:  Arch Dis Child       Date:  2006-04       Impact factor: 3.791

2.  HPV vaccine: positive insights from universal adolescent HepB vaccination.

Authors:  J Claire Cameron; Lesley A Wallace; Syed Ahmed; Rina Duff; Martin Donaghy; David J Goldberg
Journal:  J Epidemiol Community Health       Date:  2007-12       Impact factor: 3.710

Review 3.  A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus.

Authors:  Yiling Jiang; Aline Gauthier; Maarten J Postma; Laureen Ribassin-Majed; Nathalie Largeron; Xavier Bresse
Journal:  Hum Vaccin Immunother       Date:  2013-07-23       Impact factor: 3.452

4.  Ensuring access to HPV vaccines through integrated services: a reproductive health perspective.

Authors:  Amy E Pollack; Miranda Balkin; Lindsay Edouard; Felicity Cutts; Nathalie Broutet
Journal:  Bull World Health Organ       Date:  2007-01       Impact factor: 9.408

5.  Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States.

Authors:  Jane J Kim; Jesse Ortendahl; Sue J Goldie
Journal:  Ann Intern Med       Date:  2009-10-20       Impact factor: 25.391

6.  Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.

Authors:  Jeremy D Goldhaber-Fiebert; Natasha K Stout; Joshua A Salomon; Karen M Kuntz; Sue J Goldie
Journal:  J Natl Cancer Inst       Date:  2008-02-26       Impact factor: 13.506

7.  Health and economic implications of HPV vaccination in the United States.

Authors:  Jane J Kim; Sue J Goldie
Journal:  N Engl J Med       Date:  2008-08-21       Impact factor: 91.245

Review 8.  Increasing Coverage of Appropriate Vaccinations: A Community Guide Systematic Economic Review.

Authors:  Verughese Jacob; Sajal K Chattopadhyay; David P Hopkins; Jennifer Murphy Morgan; Adesola A Pitan; John M Clymer
Journal:  Am J Prev Med       Date:  2016-02-01       Impact factor: 5.043

9.  Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.

Authors:  Jane J Kim; Sue J Goldie
Journal:  BMJ       Date:  2009-10-08

10.  Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine.

Authors:  Hugo C Turner; Iacopo Baussano; Geoff P Garnett
Journal:  PLoS One       Date:  2013-09-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.